Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome
- PMID: 9061312
- DOI: 10.1046/j.1365-2362.1997.930641.x
Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome
Abstract
Patients with nephrotic syndrome have multiple abnormalities of lipoprotein metabolism, but the cause and exact nature of these abnormalities have not been established. In the present study we have determined the kinetics of plasma low-density lipoprotein (LDL) apoB in seven nephrotic patients demonstrating an elevated LDL apoB production rate (25.7 +/- 6.4 vs. 13.1 +/- 0.3 mgkg-1 day-1; P < 0.001) but a normal LDL apoB fractional catabolic rate (FCR) (0.31 +/- 0.04 vs. 0.33 +/- 0.008 pools day-1; NS) compared with 41 healthy control subjects. However, two out of the seven patients had a markedly low LDL apoB-FCR. Serum albumin was inversely correlated with the LDL apoB production rate (R = -0.82; P < 0.05). Plasma lipoprotein (a) [Lp(a)] levels were significantly (P < 0.001) increased in the nephrotic patients compared with control subjects. Significant correlations were observed between log Lp(a) and LDL apoB production rate (R = 0.90; P < 0.01), VLDL-cholesterol (R = 0.95; P < 0.001) and VLDL-triglycerides (R = 0.80; P < 0.05) respectively. In summary, the present study suggests that nephrotic hyperlipidaemia may be caused by at least two independent mechanisms. The elevated LDL apoB production rate is highly correlated with the prevailing levels of serum albumin, whereas some nephrotic patients seem to have a decreased LDL apoB clearance, suggesting impaired LDL receptor-mediated clearance. The present results also suggest that the elevated plasma Lp(a) levels in nephrosis are related to an increased hepatic synthesis rather than a decreased catabolism of lipoproteins.
Similar articles
-
Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.Kidney Int. 1998 Apr;53(4):994-1001. doi: 10.1111/j.1523-1755.1998.00831.x. Kidney Int. 1998. PMID: 9551409
-
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.Diabetes. 2003 Mar;52(3):803-11. doi: 10.2337/diabetes.52.3.803. Diabetes. 2003. PMID: 12606523 Clinical Trial.
-
Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1703-7. doi: 10.1161/01.ATV.0000137975.14996.df. Epub 2004 Jul 8. Arterioscler Thromb Vasc Biol. 2004. PMID: 15242863
-
Dyslipidemia and nephrotic syndrome: recent advances.J Ren Nutr. 2005 Apr;15(2):195-203. doi: 10.1053/j.jrn.2004.10.003. J Ren Nutr. 2005. PMID: 15827892 Review.
-
Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.Kidney Int. 2016 Jul;90(1):41-52. doi: 10.1016/j.kint.2016.02.026. Epub 2016 Apr 26. Kidney Int. 2016. PMID: 27165836 Free PMC article. Review.
Cited by
-
Acute phase reactants as novel predictors of cardiovascular disease.ISRN Inflamm. 2012 May 6;2012:953461. doi: 10.5402/2012/953461. ISRN Inflamm. 2012. PMID: 24049653 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous